	US 12,324,791 B2
	Mirdametinib treatment
Uchenna H. Iloeje, Stamford, CT (US); Abraham J. Langseth, Stamford, CT (US); and Todd Webster Shearer, Stamford, CT (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SpringWorks Therapeutics Inc., Stamford, CT (US)
Filed on Nov. 22, 2023, as Appl. No. 18/518,127.
Application 18/518,127 is a continuation of application No. 18/334,518, filed on Jun. 14, 2023, granted, now 11,883,375.
Application 18/334,518 is a continuation of application No. 18/185,148, filed on Mar. 16, 2023, granted, now 11,806,322, issued on Nov. 7, 2023.
Claims priority of provisional application 63/321,036, filed on Mar. 17, 2022.
Claims priority of provisional application 63/321,046, filed on Mar. 17, 2022.
Prior Publication US 2024/0173274 A1, May 30, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/166 (2006.01); A61K 9/00 (2006.01); A61K 31/216 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/166 (2013.01) [A61K 9/0053 (2013.01); A61K 31/216 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01); A61P 35/00 (2018.01)]

2 Claims

1. A method of treating a human patient 8 years or older who has neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) comprising orally administering an effective amount of mirdametinib to the patient, wherein an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC_0-tauless than 400 ng·h/mL, (ii) a C_maxno more than 40 ng/mL, or (iii) both, wherein, during treatment, the patient suffers from acneiform rash.